nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—P2RY12—forebrain—attention deficit hyperactivity disorder	0.0441	0.104	CbGeAlD
Epoprostenol—PTGIS—cardiovascular system—attention deficit hyperactivity disorder	0.0414	0.0973	CbGeAlD
Epoprostenol—P2RY12—cardiovascular system—attention deficit hyperactivity disorder	0.0373	0.0876	CbGeAlD
Epoprostenol—PTGIR—forebrain—attention deficit hyperactivity disorder	0.0282	0.0661	CbGeAlD
Epoprostenol—PTGIS—nervous system—attention deficit hyperactivity disorder	0.0266	0.0625	CbGeAlD
Epoprostenol—PTGIS—central nervous system—attention deficit hyperactivity disorder	0.0256	0.0601	CbGeAlD
Epoprostenol—PTGER1—nervous system—attention deficit hyperactivity disorder	0.0247	0.0581	CbGeAlD
Epoprostenol—P2RY12—nervous system—attention deficit hyperactivity disorder	0.024	0.0563	CbGeAlD
Epoprostenol—PTGER1—central nervous system—attention deficit hyperactivity disorder	0.0238	0.0559	CbGeAlD
Epoprostenol—PTGIR—cardiovascular system—attention deficit hyperactivity disorder	0.0238	0.0559	CbGeAlD
Epoprostenol—P2RY12—central nervous system—attention deficit hyperactivity disorder	0.0231	0.0542	CbGeAlD
Epoprostenol—PTGIS—brain—attention deficit hyperactivity disorder	0.0203	0.0478	CbGeAlD
Epoprostenol—P2RY12—brain—attention deficit hyperactivity disorder	0.0183	0.043	CbGeAlD
Epoprostenol—PTGIR—nervous system—attention deficit hyperactivity disorder	0.0153	0.0359	CbGeAlD
Epoprostenol—PTGIR—central nervous system—attention deficit hyperactivity disorder	0.0147	0.0345	CbGeAlD
Epoprostenol—PTGIR—cerebellum—attention deficit hyperactivity disorder	0.0144	0.0338	CbGeAlD
Epoprostenol—PTGIR—brain—attention deficit hyperactivity disorder	0.0117	0.0274	CbGeAlD
Epoprostenol—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00851	0.02	CbGeAlD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00744	0.013	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00708	0.0123	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00657	0.0114	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00644	0.0112	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00639	0.0111	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00605	0.0105	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00605	0.0105	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.006	0.0104	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00592	0.0103	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00592	0.0103	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00588	0.0102	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00588	0.0102	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00563	0.0098	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00551	0.00961	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00518	0.00902	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00518	0.00902	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00508	0.00884	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00508	0.00884	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00481	0.00837	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00478	0.00832	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00474	0.00826	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00446	0.00777	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00429	0.00747	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.0042	0.00732	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0042	0.00731	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00411	0.00715	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00411	0.00715	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00394	0.00687	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00394	0.00687	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00391	0.0068	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0039	0.00679	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00386	0.00673	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00386	0.00673	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00383	0.00668	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00382	0.00666	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00378	0.00659	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00372	0.00648	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00367	0.0064	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00363	0.00631	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00361	0.00629	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00359	0.00625	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00359	0.00625	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00353	0.00614	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00352	0.00613	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00352	0.00613	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00351	0.00612	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00345	0.00601	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00342	0.00596	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00341	0.00594	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00334	0.00582	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00334	0.00581	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00334	0.00581	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00332	0.00579	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00332	0.00579	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00328	0.00571	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00323	0.00563	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00323	0.00563	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00318	0.00553	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00318	0.00553	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00318	0.00553	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00314	0.00546	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00314	0.00546	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00311	0.00541	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00307	0.00536	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00307	0.00536	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00302	0.00526	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00302	0.00526	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00301	0.00524	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00296	0.00515	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00292	0.00509	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00292	0.00509	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00292	0.00509	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00291	0.00507	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00286	0.00498	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00286	0.00498	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00277	0.00482	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00277	0.00482	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00272	0.00474	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00272	0.00474	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00272	0.00474	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STUB1—attention deficit hyperactivity disorder	0.00272	0.00473	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00269	0.00468	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00269	0.00468	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00268	0.00467	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00268	0.00467	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00265	0.00461	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00254	0.00443	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.0025	0.00436	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.0025	0.00436	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00242	0.00422	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00237	0.00413	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00237	0.00412	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00237	0.00412	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00234	0.00408	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00234	0.00408	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00229	0.00399	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00225	0.00392	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00223	0.00388	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00223	0.00388	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00222	0.00387	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00222	0.00387	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0022	0.00383	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00218	0.0038	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00218	0.0038	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00218	0.00379	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00218	0.00379	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00216	0.00375	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00211	0.00367	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00211	0.00367	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00207	0.00361	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00207	0.00361	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00207	0.00361	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00205	0.00357	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00205	0.00357	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00205	0.00356	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00205	0.00356	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00202	0.00353	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00202	0.00353	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00201	0.00351	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00198	0.00345	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00198	0.00345	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00195	0.0034	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00194	0.00337	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00191	0.00332	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00191	0.00332	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00191	0.00332	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00185	0.00323	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00178	0.00311	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00178	0.00311	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00175	0.00305	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00175	0.00305	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00164	0.00287	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00151	0.00264	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00151	0.00264	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00151	0.00263	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00149	0.0026	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00145	0.00253	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00144	0.00251	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00144	0.0025	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00139	0.00242	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00139	0.00242	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00137	0.00239	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00137	0.00239	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00135	0.00235	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00135	0.00235	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00134	0.00233	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00134	0.00233	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00134	0.00233	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00133	0.00231	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00132	0.0023	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00132	0.0023	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00131	0.00227	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.0013	0.00226	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00129	0.00225	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SNAP25—attention deficit hyperactivity disorder	0.00129	0.00224	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00127	0.00222	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00127	0.00222	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00126	0.00219	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00125	0.00217	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00123	0.00215	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00123	0.00214	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00123	0.00214	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00121	0.00211	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.0012	0.00209	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.0012	0.00209	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.0012	0.00208	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.0012	0.00208	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00119	0.00208	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00119	0.00208	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00118	0.00205	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00117	0.00204	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00117	0.00204	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00117	0.00204	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00117	0.00204	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00117	0.00204	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00116	0.00201	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00116	0.00201	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00116	0.00201	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00115	0.002	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00115	0.002	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00114	0.00199	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00112	0.00195	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00112	0.00195	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00108	0.00188	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00108	0.00188	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00108	0.00188	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00108	0.00188	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00108	0.00188	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00106	0.00185	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00106	0.00185	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00106	0.00185	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00105	0.00183	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00105	0.00183	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00103	0.00179	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000978	0.0017	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000978	0.0017	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000882	0.00154	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00082	0.00143	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—COMT—attention deficit hyperactivity disorder	0.000817	0.00142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000812	0.00141	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000812	0.00141	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000811	0.00141	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000787	0.00137	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000772	0.00134	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000771	0.00134	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000767	0.00134	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000762	0.00133	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000755	0.00131	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000755	0.00131	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000745	0.0013	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000717	0.00125	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00071	0.00124	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00071	0.00124	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000694	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000687	0.0012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000685	0.00119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000685	0.00119	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000683	0.00119	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000674	0.00117	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00066	0.00115	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00066	0.00115	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000639	0.00111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000639	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000633	0.0011	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000628	0.00109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000628	0.00109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000628	0.00109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00062	0.00108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00062	0.00108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000578	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000578	0.00101	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00044	0.000766	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EP300—attention deficit hyperactivity disorder	0.000418	0.000729	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000405	0.000705	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000405	0.000705	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—attention deficit hyperactivity disorder	0.00035	0.00061	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000316	0.00055	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000233	0.000406	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000218	0.00038	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000218	0.00038	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000214	0.000374	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000214	0.000374	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000214	0.000373	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000199	0.000347	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000174	0.000303	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000166	0.000289	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000132	0.00023	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000131	0.000228	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000127	0.000221	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	5.66e-05	9.86e-05	CbGpPWpGaD
